China Injectable Drug Delivery Devices Market to Reach USD 8.35 Billion by 2032, Growing at a CAGR of 3.81% During 2026–2032

The China Injectable Drug Delivery Devices Market was valued at USD 4.87 billion in 2025, reached USD 6.67 billion in 2026, and is projected to attain USD 8.35 billion by 2032, expanding at a CAGR of 3.81% during the forecast period. Market growth is primarily supported by the country's rising chronic disease burden, expanding biologics adoption, increasing healthcare expenditure, and supportive regulatory initiatives aimed at accelerating innovative drug commercialization.

Additionally, government initiatives supporting biopharmaceutical innovation are strengthening the domestic ecosystem for injectable therapies and associated delivery devices. Policies promoting accelerated drug approvals, insurance coverage expansion, and commercialization pathways are creating favorable conditions for increased adoption of advanced injectable systems. Moreover, China's expanding biologics and biosimilars pipeline is generating significant opportunities for manufacturers of advanced drug delivery devices. Biologic therapies, including monoclonal antibodies and antibody-drug conjugates, require injectable administration, creating direct demand for compatible delivery technologies.

From a segment perspective, Conventional Syringes held the largest share due to their affordability, widespread availability, and extensive use in hospitals and vaccination programs. By therapeutic application, Diabetes dominated the market, supported by China's large insulin-dependent patient population and growing uptake of GLP-1 therapies. The market remains moderately consolidated, with leading companies leveraging extensive product portfolios, manufacturing capabilities, and healthcare distribution networks to strengthen their competitive positions across the country, as stated in the recent report “China Injectable Drug Delivery Devices Market Analysis, 2026”.

China Injectable Drug Delivery Devices Market Highlights

The China Injectable Drug Delivery Devices Market was valued at USD 4.87 billion in 2025, reached USD 6.67 billion in 2026, and is projected to attain USD 8.35 billion by 2032, growing at a CAGR of 3.81%.
Conventional Syringes led the product segment with approximately 32% market share, supported by cost efficiency, broad compatibility, and extensive hospital utilization.
Diabetes emerged as the leading therapeutic application, accounting for nearly 72% of market demand due to China's large insulin-dependent patient population.
Leading companies, including Becton, Dickinson and Company, Baxter International Inc., Terumo Corporation, B. Braun SE, and West Pharmaceutical Services, collectively account for approximately 30% of market revenue.